Appt of Finance Director

Alliance Pharma PLC
28 June 2007


For immediate release                                              28 June 2007


                              ALLIANCE PHARMA PLC
                         ('Alliance' or 'the Company')

                        Appointment of Finance Director

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, is
pleased to announce that Richard Wright, a Chartered Accountant with
considerable experience of quoted and private businesses across a variety of
sectors, has joined the Company, and the Company's Board, as Finance Director.

Mr Wright, aged 40 years, a Cambridge University mathematics graduate, qualified
as an accountant with Ernst & Young before joining Somerfield plc, where he
worked in various finance functions between 1993 and 1997. Mr Wright joined
FirstGroup plc in 1997 where he held senior positions including Finance Director
of Great Western Trains Co Ltd. He joins Alliance Pharma from Parragon Books
Ltd, which he joined in 2005 and where he held the role of Group Finance
Director and Company Secretary.

John Dawson, Alliance Pharma's Chief Executive, said: 'We are delighted to
welcome Richard to Alliance Pharma.  As the Company pursues its recently
announced focus on improving profitability, I believe Richard's extensive and
varied experience will make a major contribution.'

There are no further disclosures to be made in accordance with Schedule 2 (g) of 
the AIM rules.

For further information:

Alliance Pharma plc                                         + 44 (0) 1249 466966
John Dawson, Chief Executive
www.alliancepharma.co.uk

Buchanan Communications                                    + 44 (0) 20 7466 5000
Mark Court/Rebecca Skye Dietrich




Notes to editors

About Alliance Pharma

Alliance Pharma, founded in 1996, is an AIM listed emerging speciality
pharmaceutical company based in Chippenham, Wiltshire, UK. The company has a
strong track record of acquiring the rights to established niche brands and
owns, or shares, the rights to 34 branded pharmaceutical products.

Alliance Pharma's products are prescribed in the treatment of a wide range of
conditions and include brands used in periodontitis (a serious gum disease), the
prevention of heart disease, in Parkinson's disease, in nutrition, in nasal
infections, in the treatment of dermatological conditions and in childbirth.
Alliance Pharma's sales are mainly prescription driven.  Its products are
distributed to hospitals directly and to pharmaceutical wholesalers which
service both hospital and retail pharmacies with their prescription
requirements.

Alliance Pharma joined the AIM market of the London Stock Exchange in December
2003 and trades under the symbol APH.


                      This information is provided by RNS
            The company news service from the London Stock Exchange